CD33 and non-small cell lung carcinoma: In an NSCLC clinical trial of 89 patients, levels of S100A9+ M-MDSCs (CD33+CD14+IL-4Rα+HLA-DRlow/− cells) positively correlated with metastasis and negatively correlated with response to chemotherapy and survival time.